Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial

Genital psoriasis can be stigmatizing, is highly prevalent among patients with psoriasis, and has limited treatment options. Apremilast is a unique oral immunomodulating phosphodiesterase 4 inhibitor approved for psoriasis treatment. To assess the efficacy and safety of apremilast 30 mg twice daily...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Academy of Dermatology 2024-03, Vol.90 (3), p.485-493
Hauptverfasser:	Merola, Joseph F., Parish, Lawrence Charles, Guenther, Lyn, Lynde, Charles, Lacour, Jean-Philippe, Staubach, Petra, Cheng, Sue, Paris, Maria, Picard, Hernan, Deignan, Cynthia, Jardon, Shauna, Chen, Mindy, Papp, Kim A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Inflammatory Agents, Non-Steroidal - adverse effects apremilast Double-Blind Method efficacy genital psoriasis Genitalia Humans moderate to severe Psoriasis - chemically induced Psoriasis - diagnosis Psoriasis - drug therapy Quality of Life safety Severity of Illness Index systemic Thalidomide - analogs & derivatives Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Genital psoriasis can be stigmatizing, is highly prevalent among patients with psoriasis, and has limited treatment options. Apremilast is a unique oral immunomodulating phosphodiesterase 4 inhibitor approved for psoriasis treatment. To assess the efficacy and safety of apremilast 30 mg twice daily in patients with genital psoriasis. DISCREET, a phase 3, placebo-controlled trial (NCT03777436), randomized patients with moderate-to-severe genital psoriasis (stratified by affected body surface area
ISSN:	0190-9622 1097-6787
DOI:	10.1016/j.jaad.2023.10.020